Cargando…

Correction to: Burosumab in X-linked hypophosphatemia: a profile of its use in the USA

Detalles Bibliográficos
Autor principal:	Lyseng-Williamson, Katherine A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2018
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267538/ https://www.ncbi.nlm.nih.gov/pubmed/31186611 http://dx.doi.org/10.1007/s40267-018-0577-0

Ejemplares similares

Burosumab in X-linked hypophosphatemia: a profile of its use in the USA
por: Lyseng-Williamson, Katherine A.
Publicado: (2018)

Burosumab and Dental Abscesses in Children With X‐Linked Hypophosphatemia
por: Gadion, Margaux, et al.
Publicado: (2022)

Correction to: Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA
por: McKeage, Kate, et al.
Publicado: (2018)

Long-term Burosumab Administration Is Safe and Effective in Adults With X-linked Hypophosphatemia
por: Weber, Thomas J, et al.
Publicado: (2022)

SUN-333 Burosumab Improves Bone Density in Patients with X-Linked Hypophosphatemia
por: Murari, Keerti, et al.
Publicado: (2020)

Population Pharmacokinetics and Pharmacodynamics of Burosumab in Adult and Pediatric Patients With X‐linked Hypophosphatemia
por: Lee, Sun Ku, et al.
Publicado: (2021)

Growth pattern in children with X-linked hypophosphatemia treated with burosumab and growth hormone
por: Ertl, Diana-Alexandra, et al.
Publicado: (2022)

Correction to: Anakinra in Still’s disease: a profile of its use
por: Lyseng‑Williamson, Katherine A.
Publicado: (2018)

Positive Response to One-Year Treatment With Burosumab in Pediatric Patients With X-Linked Hypophosphatemia
por: Martín Ramos, Silvia, et al.
Publicado: (2020)

Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia
por: Ward, Leanne M, et al.
Publicado: (2022)

Effects of Burosumab Treatment on Two Siblings with X-Linked Hypophosphatemia. Case Report and Literature Review
por: Jurca, Claudia Maria, et al.
Publicado: (2022)

Correction to: Macrogol (polyethylene glycol) 4000 without electrolytes in the symptomatic treatment of chronic constipation: a profile of its use
por: Lyseng-Williamson, Katherine A.
Publicado: (2018)

Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia
por: Linglart, Agnès, et al.
Publicado: (2021)

Correction to: Pirfenidone tablets in idiopathic pulmonary fibrosis: a profile of their use
por: Lyseng-Williamson, Katherine A.
Publicado: (2018)

Clinical Evidence for the Benefits of Burosumab Therapy for X-Linked Hypophosphatemia (XLH) and Other Conditions in Adults and Children
por: Schindeler, Aaron, et al.
Publicado: (2020)

Body composition and cardiometabolic health of pediatric patients with X-linked hypophosphatemia (XLH) under burosumab therapy
por: Brener, Avivit, et al.
Publicado: (2021)

Dental health of pediatric patients with X-linked hypophosphatemia (XLH) after three years of burosumab therapy
por: Brener, Rafi, et al.
Publicado: (2022)

Burosumab for X-linked hypophosphatemia in children and adolescents: Opinion based on early experience in seven European countries
por: Mughal, M. Zulf, et al.
Publicado: (2023)

Dramatic Transformation After Burosumab in a Young Boy With X-linked Hypophosphatemia: A Life-Changing Saga
por: Baradhi, Krishna
Publicado: (2022)

Burosumab for X-linked hypophosphataemia
Publicado: (2021)

Correction to: Phenotypic characterization of X-linked hypophosphatemia in pediatric Spanish population
por: Rodríguez-Rubio, Enrique, et al.
Publicado: (2021)

Burosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose Level
por: Imel, Erik A, et al.
Publicado: (2023)

Safety and Efficacy of Burosumab in Pediatric Patients With X-Linked Hypophosphatemia: A Phase 3/4 Open-Label Trial
por: Namba, Noriyuki, et al.
Publicado: (2022)

Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA
por: McKeage, Kate, et al.
Publicado: (2018)

OR13-2 Burosumab Resulted in Greater Improvement in Rickets Than Conventional Therapy in Children with X-Linked Hypophosphatemia (XLH)
por: Imel, Erik, et al.
Publicado: (2019)

Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X‐Linked Hypophosphatemia: A Phase 3, Single‐Arm, International Trial
por: Insogna, Karl L, et al.
Publicado: (2019)

SUN-356 Burosumab Resulted in Greater Clinical Improvements Compared with Higher-dose Conventional Therapy in Children with X-linked Hypophosphatemia (XLH)
por: Imel, Erik A, et al.
Publicado: (2020)

Correction to: Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features
por: Lyseng-Williamson, Katherine A.
Publicado: (2019)

Correction to: Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features
por: Lyseng-Williamson, Katherine A.
Publicado: (2020)

What are the benefits of the anti-FGF23 antibody burosumab on the manifestations of X-linked hypophosphatemia in adults in comparison with conventional therapy? A review
por: Lafage-Proust, Marie-Hélène
Publicado: (2022)

OR13-2 Characterizing the Impact of Burosumab on Bone Health in Children with X-Linked Hypophosphatemia: Results from Year 1 of the Disease Monitoring Program
por: Carpenter, Thomas, et al.
Publicado: (2022)

Burosumab treatment in a child with cutaneous skeletal hypophosphatemia syndrome: A case report
por: Khadora, Manal, et al.
Publicado: (2021)

First‐in‐Asian Phase I Study of the Anti‐Fibroblast Growth Factor 23 Monoclonal Antibody, Burosumab: Safety and Pharmacodynamics in Adults With X‐linked Hypophosphatemia
por: Cheong, Hae Il, et al.
Publicado: (2018)

Anakinra in Still’s disease: a profile of its use
por: Lyseng-Williamson, Katherine A.
Publicado: (2018)

Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia
por: Padidela, Raja, et al.
Publicado: (2021)

A Case Report: First Long-Term Treatment With Burosumab in a Patient With Cutaneous-Skeletal Hypophosphatemia Syndrome
por: Merz, Lea Maria, et al.
Publicado: (2022)

Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use
por: Lyseng-Williamson, Katherine A.
Publicado: (2018)

Macrogol (polyethylene glycol) 4000 without electrolytes in the symptomatic treatment of chronic constipation: a profile of its use
por: Lyseng-Williamson, Katherine A.
Publicado: (2018)

Enthesopathy, Osteoarthritis, and Mobility in X-linked Hypophosphatemia
por: Imel, Erik A
Publicado: (2020)

Dental management of patients with X-linked hypophosphatemia
por: Lee, Bin-Na, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_thrflq4d3d52f7cod58lpf9qao